-
PDF
- Split View
-
Views
-
Cite
Cite
C Wall, J Weir-Mccall, K Tweed, S P Hoole, D Gopalan, Y Huang, A Corovic, M Peverelli, D Dey, M Bennett, J H F Rudd, A Kydd, S Bhagra, J M Tarkin, CT pericoronary adipose tissue density predicts coronary allograft vasculopathy and adverse clinical outcomes after cardiac transplantation, European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.150, https://doi.org/10.1093/eurheartj/ehad655.150
- Share Icon Share
Abstract
Coronary allograft vasculopathy (CAV) is a common cause of heart transplant failure. Coronary Computed Tomography Angiography (CCTA) is used to assess for luminal stenoses in patients with suspected CAV, but additional non-invasive markers are needed to detect early disease and guide the use of treatments that can prevent or slow CAV progression.
We tested the hypotheses that: 1) coronary artery inflammation assessed by pericoronary adipose tissue (PCAT) density and/or total vessel volume-to-myocardial mass ratio (V/M) measured by CCTA could improve the ability to detect CAV in heart transplant patients; and 2) these semi-automated quantitative CCTA metrics would be associated with adverse clinical outcomes.
In this retrospective observational cohort study, PCAT density, V/M, and lesion composition were measured in consecutive CCTAs from patients who underwent heart transplantation at a single site between 2010 to 2021. These parameters were incorporated into predictive models for CAV as defined by International Society for Heart & Lung Transplant criteria, and evaluated against long-term clinical outcomes.
A total of 126 CCTAs were analysed from 94 patients after heart transplant (mean age 49 [SD 14.5] years, 40% female) without CAV (n=86) and with CAV (n=40). PCAT density was higher in transplant patients with CAV (-73.0 HU [SD 9.26]) than without CAV (-77.9 HU [SD 8.23]), and age and sex-matched controls (n=12; -86.19 HU, [SD 5.38]), p<0.001 for both. Unlike patients with atherosclerotic coronary artery disease (n=32), CAV lesions were predominately non-calcified, comprised of mostly fibrous or fibrofatty tissue. V/M was lower in patients with CAV than without (32.4 mm3/g vs. 44.4 mm3/g, p<0.001). PCAT density and V/M improved the ability to predict CAV from AUC 0.78 to 0.87 on receiver operating characteristic analysis (Figure A) when added to donor age and donor/recipient hypertension status (p<0.0001). PCAT density above -66 HU was associated with a greater incidence of all-cause mortality (OR 16.6 95%CI 2.88-109.98, p<0.01; Figure B, box-plot) and the composite endpoint of death, CAV progression, acute rejection, and coronary revascularisation (OR 6.3 95%CI 1.6-32.9, p=0.01) over 5.25 (SD 2.1) years.

Diagnostic Benefit of CTCA Metrics

PCAT is predictor of Future Mortality
Author notes
Funding Acknowledgements: Type of funding sources: Public Institution(s). Main funding source(s): British Heart Foundation
- myocardium
- hypertension
- heart transplantation
- coronary arteriosclerosis
- lung transplantation
- coronary revascularization
- vascular diseases
- constriction, pathologic
- rejection (psychology)
- roc curve
- adipose tissue
- diagnosis
- heart
- mortality
- phenobarbital
- transplantation
- treatment outcome
- box plot
- allografting
- ct angiography of coronary arteries
- donors
- coronary inflammation
- composite outcomes